Objectives: To investigate the in vitro activity of cethromycin, a new ketolide, against Chlamydia pneumoniae.
Introduction
The ketolide class of antibacterial agents includes 14-membered ring macrolides that differ from erythromycin A in that they have a 3-keto group instead of the L-cladinose moiety in the lactone ring. Telithromycin was the first ketolide to be developed for clinical use. Another ketolide, cethromycin (formerly ABT-773), has a cyclic carbamate group at the 11, 12-position in addition to the 3-keto group. This antimicrobial agent exhibits good antibacterial activity against a broad range of respiratory pathogens, including multiresistant Streptococcus pneumoniae and staphylococci, Haemophilus influenzae, Moraxella catarrhalis, Legionella spp. and Mycoplasma pneumoniae. 1, 2 Chlamydia pneumoniae is recognized as an important pathogen of respiratory tract infections worldwide, is a common cause of pneumonia, bronchitis, pharyngitis and sinusitis, and is responsible for almost 10% of cases of community-acquired pneumonia (CAP). 3 The in vitro activity of macrolides and telithromycin against C. pneumoniae is variable, with clarithromycin showing the lowest MICs followed by telithromycin, azithromycin and erythromycin A. [4] [5] [6] [7] [8] However, the available data on the activity of cethromycin against C. pneumoniae are limited. 4 Therefore, we compared the in vitro activities of cethromycin and other macrolides and telithromycin against five standard strains and 15 wild-type Japanese isolates of C. pneumoniae.
Materials and methods

Antimicrobial agents
The antimicrobial agents tested were erythromycin A (Shionogi Co., Osaka, Japan), clarithromycin (Taisho Pharmaceutical Co., Osaka, Japan), azithromycin (Pfizer Pharmaceutical Co., Tokyo, Japan), telithromycin (Aventis Pharma Co., Tokyo, Japan) and cethromycin (Dainabbott Laboratories, Osaka, Japan). Solutions of the agents were prepared following the manufacturers' instructions.
Isolates
Twenty C. pneumoniae isolates were used in this study. TW-183, AR-39 and AR-388 were obtained from the Washington Research Foundation, Seattle, WA, USA. IOL-207 and Kajaani-6 were acquired from P. Saikku, National Public Health Institute, Oulu, Finland. Fifteen wild-type isolates (designated KKpn-1 to KKpn-15) were also tested, which were isolated from nasopharyngeal swab specimens collected from patients with acute respiratory tract infections at Kawasaki Medical School Hospital, Japan. The organisms from these clinical samples were positively stained with C. pneumoniae-specific monoclonal antibody. These clinical isolates were morphologically different from TWAR (TW-183, AR-39 and AR-388) strains from the United States (examples are given in Figure 1 ). 3 KKpn-15 elementary bodies (EBs) have a narrow periplasmic space and 
Measurement of MICs and minimal chlamydiacidal concentrations (MCCs)
One millilitre of culture medium [Eagle's minimal essential medium (Nissui Pharmaceuticals Co., Tokyo, Japan) and 10% heat-inactivated fetal calf serum (GIBCO BRL Life Technologies Inc., Grand Island, NY, USA)] containing 10 5 HEp-2 cells per mL were dispensed into each well of plastic 24-well culture plates, which were then incubated in 5% CO 2 at 35°C for 48 h. After confirming growth of a confluent monolayer, the culture fluid was removed from the wells by aspiration. Next, 10 4 inclusion-forming units per mL of each chlamydial strain were inoculated into each well. Then the plates were centrifuged at 900g for 60 min, and 1 mL of each preparation of the culture medium containing 1 mg/L cycloheximide (Nakarai Tesque Inc., Tokyo, Japan) and one concentration (final concentrations; range from 0.008 to 2 mg/L) of the test antibiotic were dispensed into each well. After incubation in 5% CO 2 at 35°C for 72 h, the cultures were fixed and stained for inclusions with the fluorescein isothiocyanate-conjugated monoclonal antibody specific for the chlamydial genus-specific antigen (Chlamydia FA Seiken; Denka Seiken, Tokyo, Japan). The MIC was defined as the lowest concentration at which no inclusions were found. The MCCs were determined by aspirating the antibiotic-containing medium, washing the wells twice with phosphate-buffered saline, and adding antibiotic-free medium. The infected cells were frozen at -70°C, thawed, passed onto new cells, incubated for 72 h, and then fixed and stained as described above. The MCC was the lowest antibiotic concentration resulting in no inclusions after passage. All tests were run in triplicate. Antichlamydial activity was determined when the same results were observed in at least two out of three experiments.
Results
The MIC and MCC ranges of cethromycin and the other antimicrobial agents for C. pneumoniae used in this study are shown in Table 1 . The MICs and MCCs of cethromycin for the 20 C. pneumoniae isolates both ranged between 0.016 and 0.031 mg/L. The MICs of cethromycin, telithromycin, clarithromycin, azithromycin and erythromycin A at which 90% of the isolates were inhibited (MIC 90 ) were 0.016, 0.063, 0.063, 0.25 and 0.25 mg/L, respectively. The MCC 90 of cethromycin was also 0.016 mg/L. Cethromycin was the most active antibiotic tested in this study.
Discussion
C. pneumoniae is a well-known respiratory pathogen that causes upper and lower respiratory tract infections and pneumonia. Macrolides and ketolides have been demonstrated to be active in vitro against C. pneumoniae. [4] [5] [6] [7] [8] We have previously reported on the experimental effectiveness of macrolides against acute chlamydial respiratory tract infections. 6, 7 The therapeutic effect of a 7 day course of clarithromycin at doses of 5 and 10 mg/kg body weight administered orally twice daily and of azithromycin at a dose of 10 mg/kg body weight administered orally once daily to mice with experimental Chlamydia psittaci pneumonia was excellent, with a 100% survival rate at 14 or 21 days after infection. This finding was the same as that for treatment with minocycline administered at 10 mg/kg twice daily. 6, 7 Recently, Hammerschlag et al. 9 reported a study assessing the efficacy of cethromycin for treatment of C. pneumoniae pneumonia. They found a 100% efficacy in eradication of the organism from the nasopharynx of patients with CAP. Telithromycin (given at a dosage of 800 mg once daily for 7-10 days) also showed good clinical efficacy against CAP due to C. pneumoniae. 10, 11 However, the diagnosis of C. pneumoniae infection in these telithromycin studies was based entirely on serology, not culture. Clinical studies on erythromycin A, clarithromycin and azithromycin in which cultures were carried out demonstrated that these macrolides are effective drugs for the treatment of respiratory infection associated with C. pneumoniae. 12, 13 The available data on the activity of cethromycin against C. pneumoniae are limited. Strigl et al. 4 found that both the MIC 50 and MIC 90 values of cethromycin against 20 isolates of C. pneumoniae including two reference strains, TW-183 and AR-39, were 0.015 mg/L.The MIC 90 and MCC 90 against 20 isolates of C. pneumoniae found in our study are also consistent with their report. Based on the above 
